The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10844 malaria professionals are enjoying the free benefits of MalariaWorld today


Not Open Access | Increase of dose associated with decrease in protection against controlled human malaria infection by PfSPZ Vaccine in Tanzanian adults

December 2, 2019 - 15:12 -- NOT Open Access
Jongo SA, Church LWP, Hoffman SL, et al.
Clin Infect Dis. 2019 Nov 29. pii: ciz1152

A vaccine would be an ideal tool for reducing malaria’s impact. PfSPZ Vaccine (radiation attenuated, aseptic, purified, cryopreserved Plasmodium falciparum [Pf] sporozoites [SPZ]) has been well tolerated and safe in >1,526 malaria-naïve and experienced 6-month to 65-year-olds in the U.S., Europe, and Africa. When vaccine efficacy (VE) of 5 doses of 2.7x105 PfSPZ of PfSPZ Vaccine was assessed in adults against controlled human malaria infection (CHMI) in the U.S. and Tanzania and intense field transmission of heterogeneous Pf in Mali, Tanzanians had the lowest VE (20%).

Subscribe to RSS - protection